Equities
Health CarePharmaceuticals and Biotechnology
  • Price (USD)51.59
  • Today's Change-0.75 / -1.43%
  • Shares traded19.74m
  • 1 Year change-22.46%
  • Beta0.3746
Data delayed at least 15 minutes, as of Mar 18 2024 20:10 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule drugs, products produced from biological processes, called biologics and chimeric antigen receptor (CAR-T) cell therapies. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are used as well. Biologics are administered to patients through injections or by intravenous infusion. Its in-line products include Eliquis, Opdivo, Orencia, Pomalyst/Imnovid, Yervoy, Sprycel, Reblozyl, Opdualag, Abecma, Zeposia, and others. The Company's product pipeline includes Krazati, MRTX1719, RYZ101, KarXT, ORM-6151, and Repotrectinib.

  • Revenue in USD (TTM)45.01bn
  • Net income in USD8.03bn
  • Incorporated1933
  • Employees34.10k
  • Location
    Bristol-Myers Squibb CoRoute 206 And Province Line RoadPRINCETON 08543United StatesUSA
  • Phone+1 (609) 252-4621
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bms.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BMY:NYQ since
announced
Transaction
value
RayzeBio IncDeal completed26 Dec 202326 Dec 2023Deal completed-1.34%4.21bn
Karuna Therapeutics IncAnnounced22 Dec 202322 Dec 2023Announced0.64%13.57bn
LianBio-Mavacamten Greater China RightsAnnounced24 Oct 202324 Oct 2023Announced-7.88%350.00m
Mirati Therapeutics IncDeal completed08 Oct 202308 Oct 2023Deal completed-8.95%5.12bn
Data delayed at least 15 minutes, as of Mar 18 2024 20:10 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zoetis Inc8.54bn2.34bn79.01bn14.10k34.0315.8327.919.255.075.0718.4810.900.5851.036.78605,957.4016.0214.4719.3717.1870.4769.8027.3925.772.0017.150.568226.895.747.9610.8811.1316.7124.37
Gilead Sciences, Inc.27.12bn5.66bn91.80bn18.00k16.364.0211.053.394.504.5021.5618.330.43283.955.751,506,445.008.966.7410.918.1276.0478.6420.6916.951.277.630.523481.22-0.60484.1523.370.7436-8.745.64
Vertex Pharmaceuticals Incorporated9.87bn3.62bn105.31bn5.40k29.355.9827.7110.6713.8913.8937.8868.220.48282.106.571,827,630.0017.7119.9220.9323.6487.2187.6736.6835.853.78--0.0210.0010.5126.498.9646.5022.02--
Bristol-Myers Squibb Co45.01bn8.03bn105.84bn34.10k13.573.595.952.353.863.8621.6614.560.46894.245.011,319,824.008.383.0510.893.7676.4476.1317.867.691.3112.390.5743133.63-2.5014.8126.8410.034.927.34
Regeneron Pharmaceuticals Inc13.12bn3.95bn105.86bn13.45k27.754.0624.208.0734.7634.76115.32237.410.42110.72892.39975,256.5012.6920.1814.1923.2286.1686.6330.1438.114.94--0.0943--7.7614.34-8.8710.7219.32--
Amgen Inc28.19bn6.72bn144.09bn26.70k21.5323.1013.365.1112.4912.4952.4211.640.34741.164.391,055,805.008.2810.3610.4813.0670.1675.4123.8326.511.133.150.91259.547.093.492.52-4.368.5410.04
Pfizer Inc58.50bn2.13bn157.77bn88.00k77.771.7718.642.700.35930.356610.2915.770.27611.885.29664,738.601.038.201.3010.4069.2469.343.7122.680.6935--0.44660.11-41.707.46-93.20-7.9412.213.82
Data as of Mar 18 2024. Currency figures normalised to Bristol-Myers Squibb Co's reporting currency: US Dollar USD

Institutional shareholders

32.94%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 2023194.29m9.61%
BlackRock Fund Advisorsas of 31 Dec 2023113.63m5.62%
SSgA Funds Management, Inc.as of 31 Dec 202391.77m4.54%
JPMorgan Investment Management, Inc.as of 31 Dec 202363.17m3.12%
Capital Research & Management Co. (International Investors)as of 31 Dec 202361.53m3.04%
Geode Capital Management LLCas of 31 Dec 202340.66m2.01%
Norges Bank Investment Managementas of 31 Dec 202331.17m1.54%
Columbia Management Investment Advisers LLCas of 31 Dec 202323.88m1.18%
PRIMECAP Management Co.as of 31 Dec 202323.53m1.16%
Fidelity Management & Research Co. LLCas of 31 Dec 202322.46m1.11%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.